Literature DB >> 18525276

Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma.

Pierre Loulergue, Olivier Mir, Jérôme Allali, Jean-Paul Viard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18525276     DOI： 10.1097/QAD.0b013e328300ca98

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  3 in total

1.  Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients.

Authors:  Olivier Mir; Bernadette Dessard-Diana; Agnès Lillo-Le Louet; Pierre Loulergue; Jean-Paul Viard; Anne Langlois; Catherine Durdux; Christine Le Beller
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

2.  Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.

Authors:  Michelle A Rudek; Cathy Y Chang; Kenneth Steadman; Michael D Johnson; Naveen Desai; John F Deeken
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-02       Impact factor: 3.333

3.  Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Authors:  Pierre Loulergue; Mansouria Merad; Romain Coriat; Michel Ducreux; David Planchard; Valérie Boige; Axel Le Cesne; Thomas M Gregory; Vianney Poinsignon; Angelo Paci; Olivier Mir
Journal:  Invest New Drugs       Date:  2016-11-12       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.